Physicians' Academy for Cardiovascular Education

PCI does not reduce primary endpoint in patients with severe ischemic LV systolic dysfunction

News - Aug. 30, 2022

REVIVED – Percutaneous Revascularisation for ischemic ventricular dysfunction

Presented at the ESC congress 2022 by: Prof. Divaka Perera, MD- London, UK

Introduction and methods

Although there is no evidence from randomized trials that support percutaneous coronary intervention (PCI) in patients with severe left ventricular dysfunction, this procedure is frequently performed in route clinical practice. In the ESC guidelines the recommendation has a class 2a, with Level of Evidence C and the AHA do not offer recommendations for this procedure.

In the REVIVED trial, patients with severe ventricular dysfunction (ejection fraction ≤35% and extensive coronary disease [BCIS-JS≥6) were enrolled. Patients needed to have a minimum amount of viable myocardium (as shown by CMR, OSE, SPECT or PET) of ≥4 dysfunctional segments that were viable and could be revascularized by PCI. Patients were randomized to PCI and optimal medical therapy (OMT) or OMT alone. Echocardiography was performed at 6 months and 12 months, and clinical, ICD and biochemical follow up was done at 6, 12 and 24 months.

Median follow-up was 3.4 years.

Main results


The REVIVED trial – the first randomized trial in this arena – demonstrated that PCI did not reduce the incidence of all-cause death or hospitalization for HF.

Perera said the key take home message is that this definitive results should allow guidelines to be strengthened and clinical practice to be rationalized.

The findings of this trial were simultaneously published in N Eng J Med

Share this page with your colleagues and friends: